12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sitavig acyclovir Lauriad regulatory update

BioAlliance said FDA approved an NDA for Sitavig acyclovir Lauriad to treat recurrent orofacial herpes. The company said it plans to seek a commercialization partner for...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >